Browse by Track

9: DNA methylation-based tumor microenvironment deconvolution in clear cell renal cell carcinoma reveals significant survival association with specific cell types

10: Epigenetic Dysregulation Activates the Oncogenic Dicarboxylic Amino Acid Transporter SLC1A1 in ccRCC

11: Differentiation Clear Cell Renal Cell Carcinoma from Other Common Malignant and Benign Renal Masses on Multiphasic MRI: A Likert Based Multireader Analysis

12: Outcomes of active surveillance for young and healthy patients with small renal masses

48: A Case of Metastatic Renal Cell Carcinoma to The Maxillary Sinus Initially Presenting as Recurrent Epistaxis

13: The Role of Exercise on the Physical and Mental Health of Kidney Cancer Patients and Survivors

14: Risk factors for end stage renal disease after treatment of renal cell carcinoma

15: Survival Outcomes Following Adoption of Risk-Adjusted AUA Surveillance Guidelines After Partial Nephrectomy

16: Artificial intelligence modelling to predict the risk of cardiotoxicity among renal cell carcinoma patients treated with vascular endothelial growth factor receptors tyrosine kinase inhibitors.

17: Kidney cancer clinical trials: a decision aid for patients and clinicians

18: Non-Index vs Index Readmissions Following Radical Nephrectomy: Causes, Costs, and Outcomes

19: Non-Index vs Index Readmissions Following Partial Nephrectomy: Causes, Costs, and Outcomes

20: Real-world Clinical Outcomes of Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Pembrolizumab + Axitinib (P+A) vs Ipilimumab + Nivolumab (I+N)

21: Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression

22: Healthcare resource utilization (HCRU) and costs in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line (LOT1) pembrolizumab + axitinib (P+A) or ipilimumab + nivolumab (I+N)

23: Real-world Assessment of Changing Treatment Patterns and sequence for patients with Metastatic Renal Cell Carcinoma (mRCC) in the first-line (1L) setting

24: Depth of response associated with first-line immunotherapy-based combinations in metastatic clear cell renal cell carcinoma.

25: Clinical manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort

28: Treatment decisions among patients newly diagnosed with clinical T1 renal masses

29: Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint therapy (ICT)

30: Treatment-free survival (TFS) in patients with advanced renal cell carcinoma (aRCC) treated with nivolumab and ipilimumab (NIVO/IPI) versus sunitinib (SUN): 60-month update of Checkmate 214

31: Updated efficacy of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study

32: Efficacy and safety of nivolumab plus ipilimumab versus sunitinib for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up

33: Long-term PFS from TIVO-3: Tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC

34: Characterization of Patients Undergoing Consolidative Nephrectomy after Immunotherapy

35: Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial

36: Impact of subsequent therapies in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab or sunitinib in the CLEAR study

37: A randomized phase 2 study with a cell-based immune primer plus sunitinib versus sunitinib aone in metastatic Renal Cell Carcinoma.

38: Association between depth of response (DepOR) and clinical outcomes: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER

39: Maturation of overall survival (OS) in TIVO-3 with long-term follow-up

40: Phase 1 trial of combination therapy with avelumab and cabozantinib in patients with newly diagnosed metastatic clear cell renal cell carcinoma

41: Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgery and ablation

49: A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

50: TiNivo-2: A Phase 3 Study to Compare Tivozanib+Nivolumab to Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Who Have Progressed Following ≤2 Lines of Therapy including an Immune Checkpoint Inhibitor (ICI)

51: A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo)

52: LITESPARK-011: a randomized, phase 3 study of belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/PD-L1 therapy in patients with advanced renal cell carcinoma

53: Phase 2 trial for sequential treatment after cabozantinib progression in metastatic renal cell carcinoma (Seq-Cabo)

54: APART – A Phase 2 trial of Axitinib, Palbociclib and Avelumab as advanced Clear Cell Renal Cell Carcinoma (ccRCC) Therapy

55: A pilot study of the immunomodulatory agent acarbose in combination with standard therapy in metastatic renal cell carcinoma (RCC)

43: Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma

44: NF2-Mutant Renal Cell Carcinoma: A Comprehensive Characterization of a Lethal Unclassified Renal Cell Carcinoma

45: Metagenomic analysis of the gut microbiome in metastatic renal cell carcinoma patients with sarcopenia

46: Prospective evaluation of mutation concordance between standard-of-care renal mass biopsy and nephrectomy specimens in small renal masses

47: Epigenetic, transcriptional, and compositional shifts in clear cell renal cell carcinomas